Intravitreal bevacizumab treatment of retinal telangiectasis complicated by subretinal neovascularization.

Abstract

BACKGROUND:

Idiopathic perifoveal telangiectasia (IPT) is a disorder characterized by focal parafoveal capillary dilatation of unknown cause. Photodynamic therapy (PDT) was reported to be efficacious in the treatment of subretinal neovascularization (SRN) associated with idiopathic juxtafoveal retinal telangiectasis. However, visual improvement is limited.

METHODS:

We describe the clinical, angiographic, and optical coherence tomography findings for a patient with IPT complicated with SRN and treated with PDT and bevacizumab.

RESULTS:

The patient underwent 2 sessions of PDT; however, metamorphopsia persisted, and visual acuity further decreased to 20/100 after the second PDT. Two injections of intravitreal bevacizumab (1.25 mg) were administered after PDT. Visual acuity increased dramatically from 20/100 to 20/25 after the injections. Four months after the second injection, there was no recurrence, and the patient was asymptomatic.

CONCLUSION:

Intravitreal bevacizumab treatment should be considered for patients with SRN associated with perifoveal telangiectasis, especially after insufficient therapeutic response to PDT.

• Authors: Mehmet Cakir, Zerrin Bayraktar, Sukru Bayraktar, Alper Agca, Omer Faruk Yilmaz
• Journal: Retinal cases & brief reports (Retin Cases Brief Rep) Vol. 2 Issue 2 Pg. 141-4 ( 2008) ISSN: 1935-1089 [Print] United States
• PMID: 25389826 (Publication Type: Journal Article)